Epidural Abscess Treatment Global Market Report 2024

The global epidural abscess treatment market has grown strongly in recent years. It will grow from $38.33 billion in 2023 to $41.11 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of epidural abscesses, high healthcare expenditure, increasing awareness of the disease, growing demand for combination therapies.

The global epidural abscess treatment market is expected to see strong growth in the next few years. It will grow to $52.89 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growing geriatric population, government initiatives, investment in epidural abscess research and development, growing incidence of spinal epidural abscesses. Major trends in the forecast period include innovations in healthcare technology, digital health technologies in epidural abscess care, artificial intelligence (ai) in epidural abscess diagnosis and treatment, affordable epidural abscess treatments.

The growth of the epidural abscess treatment market is expected to be driven by the rising prevalence of neurological disorders. Neurological disorders encompass medical conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. Common examples of neurological disorders include acute spinal cord injury, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), among others. Epidural abscess treatment is a crucial approach for managing these neurological disorders. It typically involves timely surgical drainage of the abscess and antibiotic therapy, which helps prevent compression of the spinal cord and nerves, relieving pressure. For instance, as of March 2022, the Alzheimer's Association, a nonprofit organization in the United States, reported that approximately 6.7 million Americans aged 65 and older are living with Alzheimer's in 2023. This number is projected to increase to 12.7 million by 2050. Consequently, the growing prevalence of neurological disorders is serving as a driving factor for the expansion of the epidural abscess treatment market.

The increasing prevalence of intravenous drug use is expected to be a driving force in the growth of the epidural abscess treatment market in the future. Intravenous drug use, which involves the direct injection of substances into the bloodstream using hypodermic needles and syringes, can result in epidural abscess when contaminated injection equipment or drugs introduce harmful bacteria or pathogens into the bloodstream. This heightened risk of epidural abscess due to intravenous drug use has created a demand for specialized care, treatments, and preventive measures. For instance, as reported by the United Nations Office on Drugs and Crime in June 2023, there was a global estimate of 13.2 million people engaged in injecting drugs in 2021, signifying an 18% increase from the 11.2 million reported in 2020. Hence, the growing incidence of intravenous drug use is poised to be a significant driver of the epidural abscess treatment market's expansion.

Major players in the epidural abscess treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma, Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, UCB Pharma, Sun Pharmaceutical Industries Limited, Kyowa Hakko Kirin Co. Ltd., Ferring B.V., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Limited, Alembic Limited, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals.

The elevated expenses linked to the treatment of epidural abscesses may significantly impede the growth of the epidural abscess treatment market. The costs associated with treating epidural abscesses can be substantial and can vary based on multiple factors, including surgical interventions, antibiotic therapy, the duration of hospitalization, and individual patient considerations. For instance, data from September 2021, published by Elsevier Inc., a Netherlands-based academic publishing company, highlights that treating epidural abscesses can be costly, especially if patients require an extended hospital stay, contributing to increased treatment expenses. Hence, the high treatment costs associated with epidural abscesses can present a hindrance to the expansion of the epidural abscess treatment market.

In March 2022, AbbVie Inc., a pharmaceutical company based in the United States, completed the acquisition of Syndesi Therapeutics SA for an approximate sum of $1 billion. This strategic acquisition is poised to facilitate AbbVie Inc.'s expansion within the field of neuroscience by incorporating novel synapse vesicle protein 2A modulators into its portfolio. Syndesi Therapeutics SA, headquartered in Belgium, is a biotechnology company with a focus on the development of therapies for spinal disorders, including conditions such as epidural abscesses.

Rise In Healthcare Expenditures

North America was the largest region in the epidural abscess treatment market in 2023. The regions covered in epidural abscess treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epidural abscess treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of epidural abscesses are intracranial and intraspinal. An intracranial epidural abscess refers to an infection between the skull's bones and the membranes encasing the brain and spinal cord. These can be treated by various treatments, including antifungals, antibiotics and surgery, which are used by various end-users, such as hospitals, pharmacies, specialty clinics and others.

This report provides epidural abscess treatment market statistics, including epidural abscess treatment industry global market size, regional shares, competitors with an epidural abscess treatment market share, detailed epidural abscess treatment market segments, market trends and opportunities and any further data you may need to thrive in the epidural abscess treatment industry. This epidural abscess treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epidural abscess treatment market consists of revenues earned by entities by providing surgical intervention, myelography, magnetic resonance imaging (MRI) and computed tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidural abscess treatment market also includes sales of vancomycin, gentamicin and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.